HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors Discovery of unique combination of cytokines in multi-functional fusion protein molecule that exhibits ability to expand TPEX cells without cytokine storm in preclinical studies Definitive data from preclinical studies shared at Scientific Seminar Series held at Nova Southeastern University on September 12, 2025, in Fort Lauderdale, Florida MIRAMAR, Fla., Sept. ...